Archive · 23 Jul 2025
Dr. Reddy's Q1 Earnings Impacted, Eyes Weight-Loss Drug Launch
Imagine a company called Dr. Reddy's that makes medicines.
They had a bit of a tough time in the US because one of their popular medicines had its price go down.
Even though things were a bit slower in the US, the company still made more money overall.
They're planning to launch a weight-loss drug in many countries, which they hope will bring in lots of money.
They are also in a small legal issue with another company about their weight loss drug in India.
They are hoping the new drug will help them grow more.
Dr. Reddy's US generics business saw an 11% year-on-year revenue decline in Q1.
Overall revenue from operations increased 11% year-on-year to ₹8,545 crore.
Profit after tax rose 2% year-on-year to ₹1,418 crore, missing estimates.
The company plans to launch weight-loss drug semaglutide in 87 countries.
Dr. Reddy's is involved in a patent dispute with Novo Nordisk in India regarding semaglutide.
- Who
- Dr. Reddy's Laboratories Ltd.
- What
- Dr. Reddy's Q1 earnings and future plans for the weight-loss drug semaglutide.
- When
- Q1 of FY26
- Where
- United States, Europe, India, and 87 countries for the weight-loss drug launch.
- Why
- The US generics business faced price erosion, and the company is aiming for future growth through the semaglutide launch.
Dr. Reddy's
Novo Nordisk
Patent Disputes
Dr. Reddy's
Dr. Reddy's expects sales of semaglutide and other GLP-1s to be huge growth drivers.
Novo Nordisk
Novo Nordisk is the innovator of semaglutide, and Dr. Reddy's has a patent dispute with them in India.
- US Generics Revenue Decline
- 11% year-on-year
- Overall Revenue (Q1)
- ₹8,545 crore
- Profit After Tax (Q1)
- ₹1,418 crore
- EBITDA Margin (Q1)
- 26.7%
- Countries for Semaglutide Launch
- 87
- India Launch
- March 2026 (pending patent resolution)